Abstract

Transgenic chloroplast technology could provide a viable solution to the production of Insulin-like Growth Factor I (IGF-I), Human Serum Albumin (HSA), or interferons (IFN) because of hyper-expression capabilities, ability to fold and process eukaryotic proteins with disulfide bridges (thereby eliminating the need for expensive post-purification processing). Tobacco is an ideal choice because of its large biomass, ease of scale-up (million seeds per plant), genetic manipulation and impending need to explore alternate uses for this hazardous crop. Therefore, all three human proteins will be expressed as follows: a) Develop recombinant DNA vectors for enhanced expression via tobacco chloroplast genomes b) generate transgenic plants c) characterize transgenic expression of proteins or fusion proteins using molecular and biochemical methods d) large scale purification of therapeutic proteins from transgenic tobacco and comparison of current purification/processing methods in E. coli or yea

Document Type

Patent

Patent Number

US 7,741,536

Application Serial Number

11/406,522

Issue Date

6-22-2010

Current Assignee

Agency: University of Pennsylvania

Assignee at Issuance

UCFRF

College

Burnett School of Biomedical Sciences

Department

Molecular Biology & Microbiology

Allowance Date

1-28-2010

Filing Date

4-18-2006

Assignee at Filing

UCFRF

Filing Type

Nonprovisional Application Record

Donated

no

Download Patent

Share

COinS